Cargando…

Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients

BACKGROUND: The positron emission tomography (PET) ligand (68)Ga-Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although (68)Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeling...

Descripción completa

Detalles Bibliográficos
Autores principales: Ringheim, Anna, Campos Neto, Guilherme de Carvalho, Anazodo, Udunna, Cui, Lumeng, da Cunha, Marcelo Livorsi, Vitor, Taise, Martins, Karine Minaif, Miranda, Ana Cláudia Camargo, de Barboza, Marycel Figols, Fuscaldi, Leonardo Lima, Lemos, Gustavo Caserta, Colombo Junior, José Roberto, Baroni, Ronaldo Hueb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058750/
https://www.ncbi.nlm.nih.gov/pubmed/32140850
http://dx.doi.org/10.1186/s13550-020-0594-6
_version_ 1783503916139282432
author Ringheim, Anna
Campos Neto, Guilherme de Carvalho
Anazodo, Udunna
Cui, Lumeng
da Cunha, Marcelo Livorsi
Vitor, Taise
Martins, Karine Minaif
Miranda, Ana Cláudia Camargo
de Barboza, Marycel Figols
Fuscaldi, Leonardo Lima
Lemos, Gustavo Caserta
Colombo Junior, José Roberto
Baroni, Ronaldo Hueb
author_facet Ringheim, Anna
Campos Neto, Guilherme de Carvalho
Anazodo, Udunna
Cui, Lumeng
da Cunha, Marcelo Livorsi
Vitor, Taise
Martins, Karine Minaif
Miranda, Ana Cláudia Camargo
de Barboza, Marycel Figols
Fuscaldi, Leonardo Lima
Lemos, Gustavo Caserta
Colombo Junior, José Roberto
Baroni, Ronaldo Hueb
author_sort Ringheim, Anna
collection PubMed
description BACKGROUND: The positron emission tomography (PET) ligand (68)Ga-Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although (68)Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeling has not yet been reported nor have simplified methods for quantification been validated. The aims of our study were to quantify (68)Ga-PSMA-11 uptake in primary prostate cancer patients using compartmental modeling with arterial blood sampling and to validate the use of standardized uptake values (SUV) and image-derived blood for quantification. RESULTS: Fifteen patients with histologically proven primary prostate cancer underwent a 60-min dynamic (68)Ga-PSMA-11 PET scan of the pelvis with axial T1 Dixon, T2, and diffusion-weighted magnetic resonance (MR) images acquired simultaneously. Time-activity curves were derived from volumes of interest in lesions, normal prostate, and muscle, and mean SUV calculated. In total, 18 positive lesions were identified on both PET and MR. Arterial blood activity was measured by automatic arterial blood sampling and manual blood samples were collected for plasma-to-blood ratio correction and for metabolite analysis. The analysis showed that (68)Ga-PSMA-11 was stable in vivo. Based on the Akaike information criterion, (68)Ga-PSMA-11 kinetics were best described by an irreversible two-tissue compartment model. The rate constants K(1) and k(3) and the net influx rate constants K(i) were all significantly higher in lesions compared to normal tissue (p < 0.05). K(i) derived using image-derived blood from an MR-guided method showed excellent agreement with K(i) derived using arterial blood sampling (intraclass correlation coefficient = 0.99). SUV correlated significantly with K(i) with the strongest correlation of scan time-window 30–45 min (rho 0.95, p < 0.001). Both K(i) and SUV correlated significantly with serum prostate specific antigen (PSA) level and PSA density. CONCLUSIONS: (68)Ga-PSMA-11 kinetics can be described by an irreversible two-tissue compartment model. An MR-guided method for image-derived blood provides a non-invasive alternative to blood sampling for kinetic modeling studies. SUV showed strong correlation with K(i) and can be used in routine clinical settings to quantify (68)Ga-PSMA-11 uptake.
format Online
Article
Text
id pubmed-7058750
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70587502020-03-23 Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients Ringheim, Anna Campos Neto, Guilherme de Carvalho Anazodo, Udunna Cui, Lumeng da Cunha, Marcelo Livorsi Vitor, Taise Martins, Karine Minaif Miranda, Ana Cláudia Camargo de Barboza, Marycel Figols Fuscaldi, Leonardo Lima Lemos, Gustavo Caserta Colombo Junior, José Roberto Baroni, Ronaldo Hueb EJNMMI Res Original Research BACKGROUND: The positron emission tomography (PET) ligand (68)Ga-Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although (68)Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeling has not yet been reported nor have simplified methods for quantification been validated. The aims of our study were to quantify (68)Ga-PSMA-11 uptake in primary prostate cancer patients using compartmental modeling with arterial blood sampling and to validate the use of standardized uptake values (SUV) and image-derived blood for quantification. RESULTS: Fifteen patients with histologically proven primary prostate cancer underwent a 60-min dynamic (68)Ga-PSMA-11 PET scan of the pelvis with axial T1 Dixon, T2, and diffusion-weighted magnetic resonance (MR) images acquired simultaneously. Time-activity curves were derived from volumes of interest in lesions, normal prostate, and muscle, and mean SUV calculated. In total, 18 positive lesions were identified on both PET and MR. Arterial blood activity was measured by automatic arterial blood sampling and manual blood samples were collected for plasma-to-blood ratio correction and for metabolite analysis. The analysis showed that (68)Ga-PSMA-11 was stable in vivo. Based on the Akaike information criterion, (68)Ga-PSMA-11 kinetics were best described by an irreversible two-tissue compartment model. The rate constants K(1) and k(3) and the net influx rate constants K(i) were all significantly higher in lesions compared to normal tissue (p < 0.05). K(i) derived using image-derived blood from an MR-guided method showed excellent agreement with K(i) derived using arterial blood sampling (intraclass correlation coefficient = 0.99). SUV correlated significantly with K(i) with the strongest correlation of scan time-window 30–45 min (rho 0.95, p < 0.001). Both K(i) and SUV correlated significantly with serum prostate specific antigen (PSA) level and PSA density. CONCLUSIONS: (68)Ga-PSMA-11 kinetics can be described by an irreversible two-tissue compartment model. An MR-guided method for image-derived blood provides a non-invasive alternative to blood sampling for kinetic modeling studies. SUV showed strong correlation with K(i) and can be used in routine clinical settings to quantify (68)Ga-PSMA-11 uptake. Springer Berlin Heidelberg 2020-02-24 /pmc/articles/PMC7058750/ /pubmed/32140850 http://dx.doi.org/10.1186/s13550-020-0594-6 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Ringheim, Anna
Campos Neto, Guilherme de Carvalho
Anazodo, Udunna
Cui, Lumeng
da Cunha, Marcelo Livorsi
Vitor, Taise
Martins, Karine Minaif
Miranda, Ana Cláudia Camargo
de Barboza, Marycel Figols
Fuscaldi, Leonardo Lima
Lemos, Gustavo Caserta
Colombo Junior, José Roberto
Baroni, Ronaldo Hueb
Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_full Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_fullStr Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_full_unstemmed Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_short Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_sort kinetic modeling of (68)ga-psma-11 and validation of simplified methods for quantification in primary prostate cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058750/
https://www.ncbi.nlm.nih.gov/pubmed/32140850
http://dx.doi.org/10.1186/s13550-020-0594-6
work_keys_str_mv AT ringheimanna kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT camposnetoguilhermedecarvalho kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT anazodoudunna kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT cuilumeng kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT dacunhamarcelolivorsi kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT vitortaise kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT martinskarineminaif kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT mirandaanaclaudiacamargo kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT debarbozamarycelfigols kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT fuscaldileonardolima kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT lemosgustavocaserta kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT colombojuniorjoseroberto kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT baronironaldohueb kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients